P2, N=30, Not yet recruiting, Stanford University

P1, N=24, Enrolling by invitation, Stanford University | Trial completion date: May 2028 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2030 | Not yet recruiting --> Enrolling by invitation

The article provides a critical evaluation of current and developing therapeutic strategies, including antiviral agents such as favipiravir and immunomodulatory agents targeting IL-1β, tumor necrosis factor, and IL-6 signaling. Understanding the interplay between viral determinants and host immune responses is critical for the rational design of effective interventions against MAYV-induced chronic inflammation and arthritis.

P4, N=144, Active, not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

P2, N=0, Withdrawn, Sound Pharmaceuticals, Incorporated | Phase classification: P2b --> P2 | N=180 --> 0 | Trial completion date: Oct 2021 --> Jun 2026 | Unknown status --> Withdrawn | Trial primary completion date: Jun 2021 --> Jun 2026

P3, N=300, Recruiting, Nantes University Hospital | Trial completion date: Oct 2026 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Jun 2028

P2, N=0, Withdrawn, Sound Pharmaceuticals, Incorporated | N=80 --> 0 | Trial completion date: Sep 2019 --> Jun 2026 | Unknown status --> Withdrawn | Trial primary completion date: Jun 2019 --> Jun 2026

A diagnosis of statin-associated anti-HMGCR IMNM was established, and treatment with mycophenolate mofetil and intravenous immunoglobulin resulted in partial biochemical improvement...Further evaluation revealed mantle cell lymphoma with bone marrow involvement, IGH::CCND1 rearrangement, and TP53 deletion, consistent with high-risk disease. In this context, continued clinical and laboratory monitoring is appropriate in inflammatory myopathy, and new hematologic abnormalities warrant further evaluation.

Notably, Ebselen enhanced the anti-metastatic efficacy of anti-PD-L1 therapy to further suppress CRPM without augmenting toxicity. Our results establish EV-associated QSOX1-MMP2 as a pivotal regulator of metastatic niche remodeling and propose QSOX1 targeting, either alone or in combination with immune checkpoint blockade, as a promising therapeutic approach for CRPM.

P=N/A, N=600, Recruiting, Hospices Civils de Lyon | N=300 --> 600

P2/3, N=422, Not yet recruiting, Alliance for Clinical Trials in Oncology

Systemic methylprednisolone induced partial anatomic improvement but was limited by recurrence during tapering and by intraocular pressure (IOP) elevation, prompting escalation with mycophenolate mofetil and later adalimumab therapy for persistent, refractory CME. This case illustrates how anti-TNF-α therapy may be insufficient for ocular inflammatory control while precipitating paradoxical psoriasis. Optimal outcomes rely on coordinated ophthalmology-dermatovenereology care when ocular disease activity and treatment-emergent skin complications evolve in parallel.